This study aims to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with symptomatic COPD, with a history of COPD exacerbations.
Key Study Information:
A study to discover whether a new investigational medication (Tozorakimab) could help reduce the number of exacerbations for people with COPD.
30+ patients with symptomatic COPD
Speak to our study support specialist for more information on this study.
10 minutes to participate in this study
Practice - Select a study
Your practice can choose a study via our website or dedicated web application.
Practice - Review & Approve Eligible Patients
uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.
uMed - Patient Contact
We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.
For most studies, between 10-30% of patients engage with our outreach.
Patient - Consents to Join Study
Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.
Not yet registered with uMed? Join over 400 GP Practices across the UK within the uMed Research Network and take part in the COPD study. Join the uMed Research Network.
More about COPD
This is a Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with symptomatic COPD, with a history of COPD exacerbations.
Register your interest in this study
Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.